```
REGISTERED CHARITY NUMBER: 292909
```
## **`Report of the Trustees and`**
```
Unaudited Financial Statements
```
```
for the Year Ended 31 December 2021
```
```
for
```
## **`CANCER TREATMENT AND RESEARCH TRUST`**
```
Sandison Lang Limited
2 St Marys Road
Tonbridge
Kent
TN9 2LB
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
Contents of the Financial Statements
for the Year Ended 31 December 2021
```
||**`Page`**|
|---|---|
|**`Report of the Trustees`**|`1 to 11`|
|**`Independent Examiner's Report`**|`12`|
|**`Statement of Financial Activities`**|`13`|
|**`Balance Sheet`**|`14`|
|**`Notes to the Financial Statements`**|`15 to 22`|
|**`Detailed Statement of Financial Activities`**|`23 to 24`|
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Report of the Trustees`**
## **`for the Year Ended 31 December 2021`**
```
Thetrusteespresenttheirreportwiththefinancialstatementsofthecharityfortheyear ended
31December2021.ThetrusteeshaveadoptedtheprovisionsofAccountingandReportingby Charities:
StatementofRecommendedPracticeapplicabletocharitiespreparingtheiraccountsinaccordance with
the FinancialReportingStandardapplicablein the UK and Republicof Ireland(FRS 102)(effective1 January
2019).
```
## **`OBJECTIVES AND ACTIVITIES`**
## **`Objectives and aims`**
```
The CancerTreatmentand ResearchTrust(CTRT)whichwas foundedin 1985,supportsworkmainlyin the
departmentsof medicaloncologyat the West LondonCancerCentre based at Charing Cross Hospitaland in
thedepartmentofmedicaloncologyattheMountVernonCancerCentre,inNorthwood,Middlesex. The
CTRTexiststosupporttreatmentandresearchintomanyformsofmalignantdiseaseandhas been
particularlyinvolvedinunderstandinghowcertaincancersdevelop,findingbetterwaystomonitor them
anddevelopingnewanti-canceragents.Itremainscommittedtofundingresearchthatisnot adequately
funded either by the major cancer charities such as CRUK, the MRC or the pharmaceutical industry.
```
## **`ACHIEVEMENT AND PERFORMANCE`**
## **`Charitable activities`**
```
The trustees are pleased with the achievements and performance of the Trust in 2021.
```
```
In 2021 CTRT contributed to funding for:
```
```
Mount Vernon Cancer Centre:
```
- `Clinical research fellow undertaking a PhD at Brunel University`
- `Laboratory technician at Brunel University working on liquid biomarkers`
- `Bench fees for a further PhD student at Brunel University`
- `Part-time administrator for Rare Neoplasms of Gynaecological Origin, UK-wide tissue and data bank of`
- `patients with specified rare gynae cancers`
```
Charing Cross and Hammersmith Hospitals
```
```
The research supported by the CTRT can be roughly split into the following areas:
```
- `Ovarian, uterine and rare gynaecological cancers`
- `Lung Cancer`
- `Testicular and Ovarian Germ Cell Cancer (GCT)`
- `Gestational Trophoblastic Disease`
- `Melanoma`
- `Renal Cancer`
- `Targeting tumour blood vessels`
```
Detailsaboutthe research,togetherwith the relevantpublicationsand studies,are availableon the Trust's
website - cancertreatment.org.uk
```
```
Page 1
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Report of the Trustees`**
## **`for the Year Ended 31 December 2021`**
## **`FINANCIAL REVIEW`**
## **`Financial position`**
```
Thefinancialresultsfortheyearareasshowninthefinancialsectionofthisreportandcover accounting
periodof12monthsfrom01January2021to31stDecember2021.Thecarryforwardfundsasat 31st
December2021amountedto£1,049.442,ofwhich£349,411wasrestrictedand£700,031 was
unrestricted.
```
```
Wecontinuetooperateinanuncertainenvironmentaffectedbytherestrictionsimposedinresponse to
COVID-19. We monitor, evaluate and adapt fundraising activities to respond to changing regulations.
```
## **`Reserves policy`**
```
Sufficientreservesare maintainedto ensurethat all expenses,as well as futureresearchcosts,are covered
in the event no donations are received in any one year.
```
```
For many years the CTRT receivedfunds to pay for researchstaff running clinicaltrials from pharmaceutical
companiesand trialorganisations.IncreasinglythesefundshavebeenpaiddirectlytothelocalNHS Trusts
whoemploythesestaff.As of 1stJanuary2008the accountsrelatedto MountVernonCancerCentre only
include income and expenses actually paid into or out of CTRT accounts.
```
## **`FUTURE PLANS`**
## `- New charity structure`
```
In 2020,theBoardofTrusteesforCTRTwereadvisedtoimplementa newstructureforthecharityin line
withthe CharityCommission'srecommendations.The CTRThas lodgedan applicationforregistrationas a
Charitable Incorporated Organisation (CIO) using one of the models recommended.
```
## `- Investing in fundraising`
```
The CTRT updatedand approveda coupleof essentialpolicies.A smallgroup of CTRT volunteershave been
identified.Theyarebeingveryhelpfulinthedevelopmentofasocialmediapresence.Itisenvisaged that
wewillcontinuetoexpandthisgroupandexploreexpandingcurrentandimplementingnew fundraising
initiatives in the next year.
```
## `- Plans for research`
```
TheCTRTwillcontinuetosupportadiversevarietyofresearchintoseveraldifferenttypesof common
cancerssuchaslung,ovarianandmelanomaandalsorarecancerssuchasgestational trophoblastic
neoplasiaandovariangermcelltumours.Thisresearchincludesstudiesbothintheclinicandin the
laboratoryfocusedondevelopingnovelbiomarkersandcancertreatmentsemployingthe latest
technologies.Immunotherapycontinuestobeamajorareaofinterestinthecancerworldand CTRT
continuestosupportleadingresearchstudyingtheeffectsofimmunotherapyintrophoblastic,lung and
renal cancers.
```
```
Details of previous research and further details about existing projects can be found on the website.
```
```
Page 2
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Report of the Trustees`**
```
for the Year Ended 31 December 2021
```
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
## **`Governing document`**
```
Thecharityiscontrolledbyitsgoverningdocument,adeedoftrustandconstitutesan unincorporated
charity.
```
```
The CancerTreatmentand ResearchTrust(CTRT)whichwas foundedin 1985,supportsworkmainlyin the
departmentsof medicaloncologyat the West LondonCancerCentre based at Charing Cross Hospitaland in
thedepartmentofmedicaloncologyattheMountVernonCancerCentre,inNorthwood,Middlesex. The
CTRTexiststosupporttreatmentandresearchintomanyformsofmalignantdiseaseandhas been
particularlyinvolvedinunderstandinghowcertaincancersdevelop,findingbetterwaystomonitor them
anddevelopingnewanti-canceragents.Itremainscommittedtofundingresearchthatisnot adequately
funded either by the major cancer charities such as CRUK, the MRC or the pharmaceutical industry.
```
## **`Recruitment and appointment of new trustees`**
```
TheCTRTBoardofTrusteesis madeup of9 professionalswithlegalormedicalbackgroundsas regulated
bythedeedoftrustinlinewiththeCharityCommissionregulations.Cancerphysiciansdominate,in line
withtheaimsofthecharity.Thereareplanstoactivelyseeknewtrusteesofnon-medical/ legal
backgrounds.ProfessorMarciaHall,aTrusteewithCTRTforover10years,tookontheroleofChair in
2019/20.
```
## **`Organisational structure`**
```
InMay2021CTRTwasgrantedaCharitableIncorporatedOrganisation(CIO)status,withthe official
transitiondate1stofJanuary2022.Inpreparationforthis,thecharityopenedanewbankaccount and
ensuredtheTransferofAssetswascompletedinlinewiththeCharityCommissionregulations.The old
charity remains open for now.
```
```
The Trust'sAdministratorwassupportedby the Boardto ensurethe transferof othercharity's operations,
such as policies, donations and other commitments related to the charitable work of the organisation.
```
```
In 2021we mergedMountVernonand CharingCross/Hammersmithwebsitestogether.Information about
CTRT and how to support its work in different areas are available on the cancertreatment.org.uk website.
```
```
Page 3
```
## **`CANCER TREATMENT AND RESEARCH TRUST`**
## **`Report of the Trustees`**
```
for the Year Ended 31 December 2021
```
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
## **`Risk management`**
```
TheTrusteesareawareoftherisksaffectingtheTrustanditsworkandhaveensuredthatpoliciesare in
place to mitigate the effect of these risks.
```
## `- Financial risks and Investment`
```
AkeyaimoftheBoardistoensureCTRTholdsadequatereservesforworkingcapitalpurposesand has
sufficientfundstomeetcontractualliabilitiesandwindingdowncosts,iftheorganisationwereto close.
This includesredundancypay, amountsdue to creditorsand commitmentsunder contracts.CTRT'slevel of
reservesalsohelpstheorganisationtoplanexpenditureagainstvariationsinthewayfundingis received.
Tobalancetheuncertaintyof funding,ourpolicyis tomaintainfinancialreservestocoverthesecosts and
allowforanorderlywinddown.Thecurrentestimateofthesecostsisc£20,000-£30,000. Without
currentlevelofsupportfromourindividualdonorsandbasedoncurrentexpenditurelevels,CTRT is
estimatedtostillremaininapositiontocoverthesecostsforthecomingxxxmonthsasour unrestricted
reserves stand at about £xxx
```
## `- Governance structure`
```
Thereviewofgovernancestructure,policiesandprocedureswascommencedandfollowingthat review,
any recommendations made and agreed upon by the trustees will be implemented in the authorised order.
```
```
Page 4
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Report of the Trustees`**
```
for the Year Ended 31 December 2021
```
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
```
CONCLUSION
```
```
Research, either totally or partly funded by the CTRT led to 40 publications in 2021.
```
```
1. SaraviS, Alizzi Z, Tosi S, Hall M, KarterisE.Preclinicalstudies on the effect of rucaparibin ovarian cancer:
impact of BRCA2 status. Cells 2021, 10, 2434 doi.org/10.3390/cells10092434
```
```
2.KatopodisP,AnikinV, KishoreU,CarterT,HallM,AsadiN, PolychronisA, KarterisE. Circulating tumour
cellsandcirculatingcell-freeDNAinpatientswithlungcancer:acomparisonbetweenthoracotomy and
video-assistedthorascopicsurgery.BMJOpenRespirRes.2021Sep;8(1):e000917. doi:
10.3390/cells10092434.PMID: 34493540
```
```
3.KerslakeR,HallM,VagnarelliP,JeyaneethiJ,RandevaHS,PadosG,KyrouI,KarterisE.A pancancer
overviewofFBN1,asprosinanditscognatereceptorOR4M1withdetailedexpressionprofilingin ovarian
cancer. Oncol Lett. 2021 Sep;22(3):650. doi: 10.3892/ol.2021.12911. Epub 2021 Jul 9.PMID: 34386072
```
```
4. BanerjeeSN, Tang M, O'ConnellRL, SjoquistK, Clamp AR, Millan D, NottleyS, Lord R, MullasseryVM, Hall
M, GourleyC, BonaventuraT, GohJC, SykesP, GrantPT,McNallyO, AlexanderL, KellyC, CartyK, Divers L,
BradshawN,EdmondsonRJ,FriedlanderM;PARAGONinvestigators.Aphase2studyofanastrozole in
patientswithoestrogenreceptorand/progesteronereceptorpositiverecurrent/metastaticgranulosa cell
tumours/sex-cordstromaltumoursof theovary:ThePARAGON/ANZGOG0903trial.GynecolOncol. 2021
Aug 16:S0090-8258(21)00586-2. doi: 10.1016/j.ygyno.2021.07.024. Online ahead of print.PMID: 34412908
```
```
5.ZahraA,DongQ,HallM,JeyaneethiJ,SilvaE,KarterisE,SisuC.IdentificationofPotentialBisphenol A
(BPA)ExposureBiomarkersinOvarianCancer.JClinMed.2021May5;10(9):1979. doi:
10.3390/jcm10091979.PMID: 34062972
```
```
6.KatopodisP,KerslakeR, DaviesJ, RandevaHS,ChathaK, HallM,SpandidosDA,AnikinV, Polychronis A,
RobertusJL, KyrouI, KarterisE. COVID19 and SARS CoV2 hostcell entrymediators:Expressionprofiling of
TMRSS4inhealthanddisease.IntJMolMed.2021Apr;47(4):64.doi:10.3892/ijmm.2021.4897. Epub
2021 Mar 2.PMID: 33649798
```
```
7. Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, GlasspoolRM, Berek JS, de Paiva BatistaM, Hall M, Kim JW,
YeoshouaE, FujiwaraN, NamBH, PolleisS, LeeJY, StrojnaA, FarrellyL, SchwameisR, FossatiR, Darlington
AS, Lai CH, WrightAA, RosenblatO, HarterP, RoxburghP, ChowdhuryRR, ChangTC, PaolettiX, Friedlander
M;GynecologicCancerInterGroup(GCIG)symptombenefitcommittee.Incorporatingpatient centered
benefitsas endpointsin randomizedtrialsof maintenancetherapiesin advancedovariancancer:A position
paperfromtheGCIGsymptombenefitcommittee.GynecolOncol.2021May;161(2):502-507. doi:
10.1016/j.ygyno.2021.02.018. Epub 2021 Feb 19.PMID: 33612336
```
```
8. MorganR, McNeishI, CookA, JamesE, LordR, DarkG, GlasspoolR, KrellJ, ParkinsonC, PooleC, Hall M,
Gallardo-RinconD, LockleyM, EssapenS, SummerJ, AnandA, ZachariahgA, WilliamsS, JonesR, Scatchard
K,WaltherA,KimJ-W,SundarS,JaysonG,LedermannJ,ClampA.Objectiveresponsesto first-line
neoadjuvantcarboplatin-paclitaxelregimensforovarian,fallopiantube,orprimaryperitoneal carcinoma
(ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol 2021; 22: 277-88
```
```
Page 5
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
for the Year Ended 31 December 2021
```
## **`Report of the Trustees`**
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
```
9. Muhammed,A.;Fulgenzi,C.A.M*.;Dharmapuri,S.;Pinter,M.;Balcar,L.;Scheiner,B.;Jun,T.;Saeed, A.;
Hildebrand,H.;Navaid,M.;etal.TheSystemicInflammatoryResponseIdentifiesPatientswith Adverse
ClinicalOutcomefromImmunotherapyinHepatocellularCarcinoma.Cancers2021,13, x.
https://doi.org/10.3390/xxxxx. *Co-first author.
```
```
10.FulgenziC.A.M.,D'AlessioA.,TalbotT.,GennariA.,OpenshawM.,DemirtasC,CortelliniA.,and Pinato
D.J. New frontiers in the medical therapy of hepatocellular carcinoma. Chemotherapy 2021.
```
```
11.BurgioV,IavaroneM,DiCostanzoGG,MarraF,LonardiS,TamburiniE,PiscagliaF,MasiG,Celsa C,
FoschiFG,SillettaM,AmorusoDC,RiminiM,BruccoleriM,TortoraR,CampaniC,SoldàC,Viola MG,
ForgioneA,ContiF,SalaniF,CataneseS,GiacchettoCM,FulgenziC,CoppolaC,LamperticoP,Pellino A,
RancatoreG, CabibboG, RattiF, PedicaF, DellaCorteA, ColomboM, De CobelliF, AldrighettiL, Cascinu S,
CasadeiGardiniA.Real-LifeClinicalDataofLenvatinibversusSorafenibforUnresectable Hepatocellular
Carcinoma in Italy. Cancer Manag Res. 2021;13:9379-9389 https://doi.org/10.2147/CMAR.S330195
```
```
12.ParisiA., CortelliniA., VendittiO., FilippiR., SalvatoreL., TortoraG., GhidiniM., NigroO., Gelsomino F.,
ZurloV.I.,FulgenziC.,LombardiP.,RosellóKeränenS.,DepetrisI.,GiampieriR.,MorelliC.,Di MarinoP., Di
PietroF.R.,ZanalettiN.,VitaleP.,GarajovaI.,SpinelliG.P.,ZorattoF.,RobertoM.,PetrilloA.,Aimar G.,
PatrunoL.,D'OrazioC.,FicorellaC.,FerriC.,PorzioG..Post-InductionManagementinPatients With
LeftSidedRASandBRAFWild-TypeMetastaticColorectalCancerTreatedWithFirst-Line Anti-EGFR-Based
Doublet Regimens: A Multicentre Study. Frontiers in Oncology, 2021
```
```
13.D'AlessioA.andFulgenziC.A.M.Treatingpatientswithadvancedhepatocellularcarcinoma and
impaired liver function: Broadening the reach of anti-cancer therapy. Liver cancer international, 2021
```
```
14.ParisiA.,PorzioG.,CannitaK.,VendittiO.,AvalloneA.,FilippiR.,SalvatoreL.,TortoraG.,Ribelli M.,
NigroO.,GelsominoF.,SpallanzaniA.,ZurloV.,LeoS.,Dell'AquilaE.,FulgenziC.,LombardiP., Roselló
KeränenS., Aimar G., De PetrisI., GiampieriR., MorelliC., De Tursi M., Tinari N., Di PietroF.R., De Galitiis F.,
ZanalettiN.,TroianiT.,VitaleP.,GarajovaI.,GhidiniM.,SpinelliG.P.,ZorattoF.,RobertoM.,Ierino D.,
PetrilloA.,D'OrazioC.,FicorellaC.,CortelliniA. Clinicians'attitudetodoubletplusanti-EGFRversus triplet
plusbevacizumabasfirstlinetreatmentin left-sidedRASandBRAFwild-typemetastaticcolorectal cancer
patients: a multicentre, "real-life", case-control study. Clinical Colorectal Cancer, 2021.
```
```
15.RapposelliIG,ShimoseS,KumadaT,OkamuraS,HiraokaA,DiCostanzoGG,MarraF,Tamburini E,
ForgioneA, FoschiFG, SillettaM, LonardiS, Masi G, ScartozziM, NakanoM, ShibataH, KawataK, Pellino A,
VivaldiC,LaiE,TakataA,TajiriK,ToyodaH,TortoraR,CampaniC,ViolaMG,PiscagliaF,ContiF, Fulgenzi
CAM,FrassinetiGL,RizzatoMD,SalaniF,AstaraG,TorimuraT,AtsukawaM,TadaT,BurgioV,Rimini M,
CascinuS, Casadei-GardiniA. Identificationof lenvatinibprognosticindexvia recursivepartitioning analysis
in advanced hepatocellular carcinoma. Esmo open, 2021
```
```
16.FulgenziC.A.M.,TalbotT.,MurrayS.M.,SillettaM.,VincenziB.,CortelliniA.andPinato D.J..
Immunotherapy in Hepatocellular Carcinoma. Current Treatment Options in Oncology 2021
```
```
17.DemirtasCO*,D'AlessioA*,RimassaL,SharmaR,PinatoDJetal.,2021,ALBIgrade:Evidencefor an
improvedmodelforliverfunctionalestimationinpatientswithhepatocellularcarcinoma,JHEP REPORTS,
Vol: 3 (*shared first authorship)
```
```
Page 6
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
for the Year Ended 31 December 2021
```
## **`Report of the Trustees`**
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
```
18.PinatoDJ,MarronTU,Mishra-KalyaniPS,GongY,WeiG,SzafronD,SharonE,SaeedA,Jun T,
DharmapuriS,NaqashAR,PeeraphatditT,GampaA,WangY,KhanU,MuzaffarM,NavaidM,LeeCJ, Lee
P-C,BulumulleA,YuB,PaulS,NimkarN,BettingerD,HildebrandH,AbugabalY,PressianiT,Personeni N,
D'AlessioA, Kaseb AO, Huang Y-H, Ang C, SchneiderJ, Pillai A, RimassaL, GoldbergKB, Pazdur R, Theoret M,
LemeryS,Fashoyin-AjeL,CortelliniA,PelosofLetal.,2021,Treatment-relatedtoxicityand improved
outcomefromimmunotherapyinhepatocellularcancer:EvidencefromanFDApooledanalysis of
landmarkclinicaltrialswithvalidationfromroutinepractice,EUROPEANJOURNALOFCANCER,Vol: 157,
Pages: 140-152, ISSN: 0959-8049
```
```
19.D'AlessioA, RimassaL,CortelliniA, PinatoDJetal.,2021,PD-1BlockadeforHepatocellular Carcinoma:
CurrentResearchandFutureProspects,JOURNALOFHEPATOCELLULARCARCINOMA,Vol:8, Pages:
887-897
```
```
20. PinatoDJ, TaberneroJ, BowerM, et al. Prevalenceand impactof COVID-19sequelaeon treatment and
survivalofpatientswithcancerwhorecoveredfromSARS-CoV-2infection:evidencefromthe OnCovid
retrospective,multicentreregistrystudy.TheLancetOncology.Publishedonline 2021.
doi:https://doi.org/10.1016/S1470-2045(21)00573-8
```
```
21.PinatoDJ,PatelM,ScottiL,ColombaE,DollyS,LoizidouA,ChesterJ,MukherjeeU,ZambelliA, Dalla
PriaA, Aguilar-CompanyJ, BowerM, SalazarR, BertuzziA, BrunetJ, LambertiniM, TagliamentoM, Pous A,
Sita-LumsdenA, SrikandarajahK, ColombaJ, PommeretF, Seguí E, GeneraliD, GrisantiS, PedrazzoliP, Rizzo
G,LibertiniM,MossC,EvansJS,RussellB,HarbeckN,VincenziB,BielloF,BertulliR,OttavianiD,Liñan R,
RossiS,Carmona-GarcíaMC,TondiniC,FoxL,BaggiA,FotiaV,ParisiA,PorzioG,QueiroloP,Cruz CA,
Saoudi-GonzalezN,FelipE,RoquéLloverasA,Newsom-DavisT,SharkeyR,RoldánE,ReyesR,Zoratto F,
EarnshawI,FerranteD,Marco-HernándezJ,Ruiz-CampsI,GaidanoG,PatriarcaA,BrunaR,Sureda A,
Martinez-VilaC,SanchezdeTorreA,BerardiR,GiustiR,MazzoniF,GuidaA,RimassaL,Chiudinelli L,
FranchiM, KrengliM, SantoroA, PratA, TaberneroJ, VanHemelrijckM, DiamantisN, GennariA, Cortellini
A.Time-DependentCOVID-19MortalityinPatientsWithCancer:AnUpdatedAnalysisofthe OnCovid
Registry. JAMA Oncol. 2021 Nov 24. doi: 10.1001/jamaoncol.2021.6199. Epub ahead of print.
```
```
22.GarrigósL,SauraC,Martinez-VilaC,ZambelliA,BowerM,PistilliB,LambertiniM,Ottaviani D,
DiamantisN,LumsdenA,PernasS,GeneraliD,SeguíE,ViñasG,FelipE,SanchezA,RizzoG,Santoro A,
CortelliniA, PeroneY, ChesterJ, IglesiasM, Betti M, VincenziB, LibertiniM, MazzoniF, ZorattoF, Berardi R,
GuidaA,WuerstleinR,LoizidouA,SharkeyR,AguilarCompanyJ,MatasM,SaggiaC,Chiudinelli L,
Colomba-BlamebleE,GalaziM,MukherjeeU,VanHemelrijckM,MarinM,StrinaC,PratA, PlaH, Ciruelos
EM, BertuzziA, Del MastroL, PorzioG, Newsom-DavisT, Ruiz I, DelanyMB, KrengliM, FotiaV, Viansone A,
ChopraN, RomeoM, SalazarR, PerezI, d'AvanzoF, FranchiM, MilaniM, PommeretF, TucciM, Pedrazzoli
P,HarbeckN,FerranteD,PinatoDJ,GennariA.COVID-19inbreastcancerpatients:asubanalysisof the
OnCovidregistry.TherAdvMedOncol.2021Nov2;13:17588359211053416. doi:
10.1177/17588359211053416.
```
```
Page 7
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
Report of the Trustees
for the Year Ended 31 December 2021
```
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
```
23.PinatoDJ,ScottiL,GennariA,Colomba-BlamebleE,DollyS,LoizidouA,ChesterJ,Mukherjee U,
ZambelliA, Aguilar-CompanyJ, Bower M, Galazi M, SalazarR, BertuzziA, Brunet J, Mesia R, Sita-Lumsden A,
ColombaJ,PommeretF,SeguíE,BielloF,GeneraliD,GrisantiS,RizzoG,LibertiniM,MossC,Evans JS,
RussellB, WuerstleinR, VincenziB, BertulliR, OttavianiD, Liñan R, MarrariA, Carmona-GarcíaMC, Sng CCT,
TondiniC,MirallasO,TovazziV,FotiaV,CruzCA,Saoudi-GonzalezN,FelipE,RLloverasA,Lee AJX,
Newsom-DavisT,SharkeyR,ChungC,García-IllescasD,ReyesR,SophiaWongYN,Ferrante D,
Marco-HernándezJ,Ruiz-CampsI,GaidanoG,PatriarcaA,SuredaA,Martinez-VilaC,SanchezdeTorre A,
RimassaL, ChiudinelliL, FranchiM, KrengliM, SantoroA, Prat A, TaberneroJ, V HemelrijckM, Diamantis N,
CortelliniA;OnCovidstudygroup.Determinantsofenhancedvulnerabilitytocoronavirusdisease2019 in
UKpatientswithcancer:aEuropeanstudy.EurJCancer.2021Jun;150:190-202. doi:
10.1016/j.ejca.2021.03.035. Epub 2021 Apr 6. PMID: 33932726; PMCID: PMC8023206.
```
```
24.SoosaipillaiG,WuA,DettorreGM,DiamantisN,ChesterJ,MossC,Aguilar-CompanyJ,BowerM, Sng
CC,SalazarR,BrunetJ,JonesE,MesiaR,JacksonA,MukherjeeU,Sita-LumsdenA,SeguíE,Ottaviani D,
CarbóA,BenafifS,WürstleinR,CarmonaC,ChopraN,CruzCA,SwallowJ,SaoudiN,FelipE,Galazi M,
Garcia-FructuosoI,LeeAJX,Newsom-DavisT,WongYNS,SuredaA,MaluquerC,Ruiz-CampsI,Cabirta A,
PratA,LoizidouA,GennariA,FerranteD,TaberneroJ,RussellB,VanHemelrijckM,Dolly S,
Hulbert-WilliamsNJ,PinatoDJ.Specialistpalliativeandend-of-lifecareforpatientswithcancer and
SARS-CoV-2infection:aEuropeanperspective.TherAdvMedOncol.2021Sep 2;13:17588359211042224.
doi: 10.1177/17588359211042224. PMID: 34497669; PMCID: PMC8419540.
```
```
25.3. DettorreGM,DollyS, LoizidouA, ChesterJ, JacksonA, MukherjeeU, ZambelliA, Aguilar-Company J,
BowerM,SngCCT,SalazarR,BertuzziA,BrunetJ,MesiaR,Sita-LumsdenA,SeguíE,BielloF,Generali D,
GrisantiS,SeevaP,RizzoG,LibertiniM,MaconiA,MossC,RussellB,HarbeckN,VincenziB,Bertulli R,
OttavianiD,LiñanR,MarrariA,Carmona-GarcíaMC,ChopraN,TondiniCA,MirallasO,TovazziV,Fotia V,
CruzCA,Saoudi-GonzalezN,FelipE,RoquéA,LeeAJX,Newsom-DavisT,García-IllescasD,ReyesR, Wong
YNS, FerranteD, ScottiL, Marco-HernándezJ, Ruiz-CampsI, PatriarcaA, RimassaL, ChiudinelliL, Franchi M,
SantoroA, Prat A, GennariA, Van HemelrijckM, TaberneroJ, DiamantisN, PinatoDJ; OnCovidstudy group.
Systemicpro-inflammatoryresponseidentifiespatientswithcancerwithadverseoutcomes from
SARS-CoV-2infection:theOnCovidInflammatoryScore.JImmunotherCancer.2021 Mar;9(3):e002277.
doi:10.1136/jitc-2020-002277.Erratumin: J ImmunotherCancer.2021Jun;9(6):PMID:33753569; PMCID:
PMC7985977.
```
```
26.JoffeJK,CaffertyFH,MurphyL,RustinGJS,SohaibSA,GabeR,StenningSP,JamesE,NoorD,Wade S,
SchiavoneF, SwiftS, DunwoodieE, Hall M, SharmaA, BraybrookeJ, ShamashJ, LogueJ, TaylorHH, Hennig
I,WhiteJ,RudmanS,WorldingJ,BloomfieldD,FaustG,GlenH,JonesR,SecklM,MacDonald G,
SreenivasanT,KumarS,ProtheroeA,VenkitaramanR,MazharD,CoyleV,HighleyM,GeldartT,Laing R,
KaplanRS,HuddartRA;TRISSTTrialManagementGroupandInvestigators.ImagingModality and
FrequencyinSurveillanceofStageISeminomaTesticularCancer:ResultsFromaRandomized,Phase III,
Noninferiority Trial (TRISST). J Clin Oncol. 2022 Aug 1;40(22):2468-2478.
```
```
27. Maher GJ, Fisher RA, Kaur B, Aguiar X, AravindP, CedenoN, Clark J, DamonD, GhoraniE, Januszewski A,
KalofonouF,MurphyR,RoyR,SarwarN,OpenshawMR,SecklMJ.NPJGenomMed.2022Apr 8;7(1):26.
doi: 10.1038/s41525-022-00297-x.PMID:35396509Sensitivescreeningof single nucleotide polymorphisms
in cell free DNA for diagnosis of gestational tumours.
```
```
Page 8
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
for the Year Ended 31 December 2021
```
## **`Report of the Trustees`**
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
```
28. GeorgiouM, NtavelouP, StokesW, Roy R, Maher GJ, StoilovaT, Choo JAMY, RakhitCP, MartinsM, Ajuh
P,HorowitzN,BerkowitzRS,EliasK,SecklMJ,PardoOE.Oncogene.2022Apr;41(18):2540-2554. doi:
10.1038/s41388-022-02251-8.Epub2022Mar18.ATRandCDK4/6inhibitiontargetthegrowth of
methotrexate-resistant choriocarcinoma.
```
```
29.ChrysostomouS,RoyR,PrischiF,ThamlikitkulL,ChapmanKL,MuftiU,PeachR,DingL,Hancock D,
MooreC, Molina-ArcasM, MauriF, PinatoDJ,AbrahamsJM,OttavianiS, CastellanoL, GiamasG, Pascoe J,
MoonamaleD, PirrieS, GauntC, BillinghamL, StevenNM, CullenM, HroudaD, WinklerM, PostJ, Cohen P,
SalpeterSJ,BarV,ZundelevichA,GolanS,LeiboviciD,LaraR,KlugDR,YalirakiSN,BarahonaM,Wang Y,
DownwardJ,SkehelJM,AliMMU,SecklMJ,PardoOE.SciTranslMed.2021Jul14;13(602):eaba4627. doi:
10.1126/scitranslmed.aba4627.PMID:34261798RepurposedfloxacinstargetingRSK4 prevent
chemoresistance and metastasis in lung and bladder cancer.
```
```
30.BragaA,PaivaG,GhoraniE,FreitasF,VelardeLGC,KaurB,UnsworthN,Lozano-KuehneJ,Dos Santos
EstevesAPV,RezendeFilhoJ,AmimJJr,AguiarX,SarwarN,EliasKM,HorowitzNS,BerkowitzRS, Seckl
MJ.LancetOncol.2021Aug;22(8):1188-1198.doi:10.1016/S1470-2045(21)00262-X.Epub2021 Jun
25.PMID:34181884Predictorsforsingle-agentresistanceinFIGOscore5or6gestational trophoblastic
neoplasia: a multicentre, retrospective, cohort study.
```
```
31. Cortés-CharryR, Hennah L, FroelingFEM, Short D, Aguiar X, Tin T, HarveyR, UnsworthN, Kaur B, Savage
P, SarwarN, SecklMJ.ESMOOpen.2021Jun;6(3):100110.doi:10.1016/j.esmoop.2021.100110.Epub 2021
Apr10.PMID:33845362Increasingthehumanchorionicgonadotrophincut-offto?1000IU/lfor starting
actinomycinDinpost-molargestationaltrophoblasticneoplasiadevelopingresistanceto methotrexate
spares more women multi-agent chemotherapy.
```
```
32.PaulNathan,JessicaC.Hassel,PiotrRutkowski,Jean-FrancoisBaurain,MarcusO.Butler,Max Schlaak,
RyanJ.Sullivan,SebastianOchsenreither,ReinhardDummer,JohnM.Kirkwood,AnthonyM. Joshua,
JosephJ.Sacco,AlexanderN.Shoushtari,MarlanaOrloff,JosepM.Piulats,MohammedMilhem,April K.S.
Salama,BrendanCurti,Lev Demidov,LaurisGastaud,CorneliaMauch,MelindaYushak,RichardD. Carvajal,
OmidHamid,ShaadE.Abdullah,ChrisHolland,HowardGoodall,andSophiePiperno-Neumann,for the
IMCgp100-202 Investigators.
```
```
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
N Engl J Med. 2021 Sep 23;385(13):1196-1206
```
```
33. AlexanderJL, IbraheimH, Sheth B, LittleJ, Khan MS, RichardsC, Hunter N, ChauhanD, Ratnakumaran R,
McHughK, PinatoDJ, NathanP, ChoyJ, CruszSM, FurnessA, TurajlicS, PickeringL, LarkinJ, TeareJP, Papa
S,SpeightA,SharmaA,PowellN.Clinicaloutcomesofpatientswithcorticosteroidrefractory immune
checkpoint inhibitor-induced enterocolitis treated with infliximab.
J Immunother Cancer. 2021 Jul;9(7)
```
```
34. Brase JC, WalterRFH, SavchenkoA, GusenleitnerD, GarrettJ, SchimmingT, VaraljaiR, CastellettiD, Kim
J, DakappagariN, SchultzK, RobertC, LongGV,NathanPD,RibasA, FlahertyKT,KaraszewskaB, Schachter
J,SuckerA,SchmidKW,ZimmerL,LivingstoneE,GasalE,SchadendorfD,RoeschA.Role of
Tumor-InfiltratingBCellsinClinicalOutcomeofPatientswithMelanomaTreatedWithDabrafenib Plus
Trametinib.
```
```
Clin Cancer Res. 2021 Aug 15;27(16):4500-4510. doi: 10.1158/1078-0432.CCR-20-3586. Epub 2021 Jun 9
```
```
Page 9
```
## **`CANCER TREATMENT AND RESEARCH TRUST`**
## **`Report of the Trustees`**
```
for the Year Ended 31 December 2021
```
## **`STRUCTURE, GOVERNANCE AND MANAGEMENT`**
```
35. Syeda MM, WigginsJM, CorlessBC, Long GV, FlahertyKT, SchadendorfD, NathanPD, RobertC, Ribas A,
DaviesMA, Grob JJ, GasalE, SquiresM, MarkerM, GarrettJ, BraseJC, PolskyD.CirculatingtumourDNA in
patientswithadvancedmelanomatreatedwithdabrafenibordabrafenibplustrametinib:a clinical
validation study.
```
```
Lancet Oncol. 2021 Mar;22(3):370-380. doi: 10.1016/S1470-2045(20)30726-9. Epub 2021 Feb 12.
```
```
36.EmmaLidington,AmyDin,SusanahStanway,AnandSharma,OlgaHusson.Describingthe supportive
careneedsamongyoungadultswithcancer(25-39years)andtherelationshipwithhealth-related quality
oflife,psychologicaldistressandillnesscognitions.JournalofClinicalMedicine,J.Clin.Med.2021, 10,
4449
```
```
37.Clinicaloutcomesofpatientswithcorticosteroidrefractoryimmunecheckpoint inhibitor-induced
enterocolitistreatedwithinfliximab.AlexanderJL,SharmaA,PowellN.JImmunotherCancer. 2021
Jul;9(7):e002742. doi: 10.1136/jitc-2021-002742. PMID: 34233964; PMCID: PMC8264884
```
```
38. Biomarkersin bladdercancersurveillance-SukumarSugeeta,SharmaAnand,KenrickNg, Nikhil Vasdev.
Frontiers in Surgery, Sept 2021; Volume 8;735868.
```
```
39.UrinaryBiomarkersinBladderCancer:AReviewofTheCurrentLandscapeandFuture Directions.
Anand Sharma, Nikhil Vasdev. Urologic Oncology. Urol Oncol. 2021 Jan;39(1):41-51
```
```
40. TreatmentOutcomesfor SmallCell Carcinomaof the Bladder:ResultsFroma UK Patient Retrospective
Cohort Study. Chau C, Sharma A, Crabb S. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1143-1150.
```
```
TheTrusteesareconfidentthattheCTRTwillcontinuetofundtheworkthatwillleadtoimprovements in
the detection, monitoring and treatment of cancer and care for patients with cancer.
```
## **`REFERENCE AND ADMINISTRATIVE DETAILS Registered Charity number`**
```
292909
```
## **`Principal address`**
```
The Clocktower
Mount Vernon Cancer Centre
Rickmansworth Road
Northwood
Middlesex
HA6 2RN
```
```
Page 10
```
## **`CANCER TREATMENT AND RESEARCH TRUST`**
## **`Report of the Trustees`**
```
for the Year Ended 31 December 2021
```
## **`Trustees`**
```
Professor G Rustin
R Ellison
Dr. P Nathan
Professor M Hall Chair of Trustees
Professor M J Seckl
Dr A Sharma
Dr A Polychronis
Dr D J Pinato
R J Hallam
```
## **`Independent Examiner`**
```
Mr Ryan Cottington, ACA, FCCA
Sandison Lang Limited
2 St Marys Road
Tonbridge
Kent
TN9 2LB
```
```
Approved by order of the board of trustees on 29 June 2023 and signed on its behalf by:
```
```
Professor M Hall - Trustee
```
```
Page 11
```
```
Independent Examiner's Report to the Trustees of
Cancer Treatment And Research Trust
```
## **`Independent examiner's report to the trustees of Cancer Treatment And Research Trust`**
```
I reportto the charitytrusteeson my examinationof the accountsof CancerTreatmentAnd Research Trust
(the Trust) for the year ended 31 December 2021.
```
## **`Responsibilities and basis of report`**
```
AsthecharitytrusteesoftheTrustyouareresponsibleforthepreparationoftheaccountsin accordance
with the requirements of the Charities Act 2011 ('the Act').
```
```
I reportin respectof myexaminationof theTrust'saccountscarriedoutunderSection145of theAct and
incarryingoutmyexaminationIhavefollowedallapplicableDirectionsgivenbytheCharity Commission
under Section 145(5)(b) of the Act.
```
## **`Independent examiner's statement`**
```
Ihavecompletedmyexamination.Iconfirmthatnomaterialmattershavecometomyattention in
connection with the examination giving me cause to believe that in any material respect:
```
`1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or`
`2. the accounts do not accord with those records; or`
`3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.`
```
Ihavenoconcernsandhavecomeacrossnoothermattersinconnectionwiththeexaminationto which
attentionshouldbedrawninthisreportinordertoenableaproperunderstandingoftheaccountsto be
reached.
```
```
Mr Ryan Cottington, ACA, FCCA
```
```
Sandison Lang Limited
2 St Marys Road
Tonbridge
Kent
TN9 2LB
```
```
29 June 2023
```
```
Page 12
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Statement of Financial Activities`**
## **`for the Year Ended 31 December 2021`**
|`Notes`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
`Other trading activities`
`2`
`Investment income`
`3`
`Other income`
**`Total`**
**`EXPENDITURE ON`**
`Raising funds`
**`Charitable activities`**
`Office expenses`
**`Total`**
**`NET INCOME/(EXPENDITURE)`**
**`RECONCILIATION OF FUNDS`**
`Total funds brought forward`
**`TOTAL FUNDS CARRIED FORWARD`**|`Unrestricted`
`fund`
`£`
**`904`**
**`-`**
**`117`**
**`-`**
**`1,021`**
**`19,060`**
**`124,909`**
**`143,969`**
**`(142,948)`**
**`842,979`**
**`700,031`**|`Restricted`
`fund`
`£`
**`137,450`**
**`41,341`**
**`-`**
**`14,700`**
**`193,491`**
**`-`**
**`477`**
**`477`**
**`193,014`**
**`156,397`**
**`349,411`**|**`2021`**
**`Total`**
**`funds`**
**`£`**
**`138,354`**
**`41,341`**
**`117`**
**`14,700`**
**`194,512`**
**`19,060`**
**`125,386`**
**`144,446`**
**`50,066`**
**`999,376`**
**`1,049,442`**|`2020`
`Total`
`funds`
`£`
`227,995`
`-`
`102`
`-`|
|---|---|---|---|---|
|||||`228,097`|
|||||`19,833`
`190,998`|
|||||`210,831`|
|||||`17,266`
`982,110`|
|||||`999,376`|
```
The notes form part of these financial statements
```
```
Page 13
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Balance Sheet`**
## **`31 December 2021`**
|`Notes`
**`FIXED ASSETS`**
`Tangible assets`
`7`
`Investments`
`8`
**`CURRENT ASSETS`**
`Debtors`
`9`
`Cash at bank`
**`CREDITORS`**
`Amounts falling due within one year`
`10`
**`NET CURRENT ASSETS`**
**`TOTAL ASSETS LESS CURRENT LIABILITIES`**
**`NET ASSETS`**
**`FUNDS`**
`11`
`Unrestricted funds`
`Restricted funds`
**`TOTAL FUNDS`**|`Unrestricted`
`fund`
`£`
**`492`**
**`6,469`**
**`6,961`**
**`933`**
**`713,642`**
**`714,575`**
**`(21,505)`**
**`693,070`**
**`700,031`**
**`700,031`**|`Restricted`
`fund`
`£`
**`685`**
**`-`**
**`685`**
**`28,398`**
**`322,483`**
**`350,881`**
**`(2,155)`**
**`348,726`**
**`349,411`**
**`349,411`**|**`2021`**
**`Total`**
**`funds`**
**`£`**
**`1,177`**
**`6,469`**
**`7,646`**
**`29,331`**
**`1,036,125`**
**`1,065,456`**
**`(23,660)`**
**`1,041,796`**
**`1,049,442`**
**`1,049,442`**
**`700,031`**
**`349,411`**
**`1,049,442`**|`2020`
`Total`
`funds`
`£`
`1,370`
`6,469`
`7,839`
`44,374`
`962,874`
`1,007,248`
`(15,711)`
`991,537`
`999,376`
`999,376`
`842,979`
`156,397`
`999,376`|
|---|---|---|---|---|
```
The financialstatementswere approvedby the Boardof Trusteesand authorisedfor issue on 29 June 2023
and were signed on its behalf by:
```
```
M Hall - Trustee
```
```
The notes form part of these financial statements
```
```
Page 14
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
Notes to the Financial Statements
for the Year Ended 31 December 2021
```
## **`1. ACCOUNTING POLICIES`**
## **`Basis of preparing the financial statements`**
```
Thefinancialstatementsofthecharity,whichisapublicbenefitentityunderFRS102,have been
preparedinaccordancewiththeCharitiesSORP(FRS102)'AccountingandReportingby Charities:
StatementofRecommendedPracticeapplicabletocharitiespreparingtheiraccountsin accordance
withtheFinancialReportingStandardapplicableintheUKandRepublicofIreland(FRS 102)
(effective1January2019)',FinancialReportingStandard102'TheFinancialReporting Standard
applicableintheUKandRepublicofIreland'andtheCharitiesAct2011.Thefinancial statements
havebeenpreparedunderthehistoricalcostconvention,withtheexceptionofinvestments which
are included at market value.
```
## **`Financial reporting standard 102 - reduced disclosure exemptions`**
```
Thecharityhastakenadvantageofthefollowingdisclosureexemptionsin preparingthese financial
statements,aspermittedbyFRS102'TheFinancialReportingStandardapplicableintheUK and
Republic of Ireland':
```
- `the requirements of Section 7 Statement of Cash Flows.`
## **`Income`**
```
Allincomeis recognisedin theStatementofFinancialActivitiesoncethecharityhasentitlement to
the funds, it is probable that the income will be received and the amount can be measured reliably.
```
## **`Expenditure`**
```
Liabilitiesarerecognisedasexpenditureassoonasthereisalegalorconstructive obligation
committingthe charityto that expenditure,it is probablethat a transferof economicbenefitswill be
requiredinsettlementandtheamountoftheobligationcanbemeasuredreliably.Expenditure is
accountedforonanaccrualsbasisandhasbeenclassifiedunderheadingsthataggregateall cost
relatedtothecategory.Wherecostscannotbedirectlyattributedtoparticularheadingsthey have
been allocated to activities on a basis consistent with the use of resources.
```
```
Grantsofferedsubjecttoconditionswhichhavenotbeenmetattheyearenddatearenotedas a
commitment but not accrued as expenditure.
```
## **`Tangible fixed assets`**
```
Depreciationisprovidedatthefollowingannualratesinordertowriteoffeachassetover its
estimated useful life.
```
```
Computer equipment- 25% on reducing balance
```
## **`Taxation`**
```
The charity is exempt from tax on its charitable activities.
```
## **`Fund accounting`**
```
Unrestrictedfundscanbe usedin accordancewiththecharitableobjectivesat thediscretionof the
trustees.
```
```
continued...
```
```
Page 15
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
```
## **`1. ACCOUNTING POLICIES - continued`**
## **`Fund accounting`**
```
Restrictedfunds can only be used for particularrestrictedpurposeswithin the objectsof the charity.
Restrictionsarisewhenspecifiedbythedonororwhenfundsareraisedforparticular restricted
purposes.
```
```
Furtherexplanationofthenatureandpurposeofeachfundis includedin thenotestothe financial
statements.
```
## **`Pension costs and other post-retirement benefits`**
```
The charityoperatesa definedcontributionpensionscheme.Contributionspayableto the charity's
pensionschemearechargedtotheStatementofFinancialActivitiesintheperiodtowhich they
relate.
```
## **`2. OTHER TRADING ACTIVITIES`**
|**`2.`**
**`OTHER TRADING ACTIVITIES`**||||
|---|---|---|---|
|`Recharged expenses`
**`3.`**
**`INVESTMENT INCOME`**
`Deposit account interest`
`Dividends`|**`2021`**
**`£`**
**`41,341`**
**`2021`**
**`£`**
**`9`**
**`108`**
**`117`**||`2020`
`£`
`-`|
||||`2020`
`£`
`102`
`-`|
||||`102`|
## **`4. TRUSTEES' REMUNERATION AND BENEFITS`**
```
Therewerenotrustees'remunerationorotherbenefitsfortheyearended31December2021 nor
for the year ended 31 December 2020.
```
```
continued...
```
```
Page 16
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
```
## **`4. TRUSTEES' REMUNERATION AND BENEFITS - continued`**
## **`Trustees' expenses`**
```
There were no Trusteeexpensespaid in the year ended 31st December2021.(£139for 1 trustee for
31st December 2020).
```
## **`5. STAFF COSTS`**
```
The average monthly number of employees during the year was as follows:
```
|`Secretary/Administration`
`No employees received emoluments in excess of £60,000.`
**`COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES`**
`Unrestricted`
`fund`
`£`
**`INCOME AND ENDOWMENTS FROM`**
`Donations and legacies`
`101,884`
`Investment income`
`102`
**`Total`**
`101,986`
**`EXPENDITURE ON`**
`Raising funds`
`19,833`
**`Charitable activities`**
`Office expenses`
`75,161`
**`Total`**
`94,994`
**`NET INCOME`**
`6,992`
**`RECONCILIATION OF FUNDS`**
`Total funds brought forward`
`835,987`
**`TOTAL FUNDS CARRIED FORWARD`**
`842,979`|**`2021`**
**`1`**
`Restricted`
`fund`
`£`
`126,111`
`-`
`126,111`
`-`
`115,837`
`115,837`
`10,274`
`146,123`
`156,397`|`2020`
`1`
`Total`
`funds`
`£`
`227,995`
`102`|
|---|---|---|
|||`228,097`|
|||`19,833`
`190,998`|
|||`210,831`|
|||`17,266`
`982,110`|
|||`999,376`|
## **`6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES`**
```
continued...
```
```
Page 17
```
## **`CANCER TREATMENT AND RESEARCH TRUST`**
## **`Notes to the Financial Statements - continued for the Year Ended 31 December 2021`**
## **`7. TANGIBLE FIXED ASSETS`**
|**`7.`**|**`TANGIBLE FIXED ASSETS`**||
|---|---|---|
|||`Computer`|
|||`equipment`|
|||`£`|
||**`COST`**||
||`At 1 January 2021`|**`3,888`**|
||`Additions`|**`199`**|
||`At 31 December 2021`|**`4,087`**|
||**`DEPRECIATION`**||
||`At 1 January 2021`|**`2,518`**|
||`Charge for year`|**`392`**|
||`At 31 December 2021`|**`2,910`**|
||**`NET BOOK VALUE`**||
||`At 31 December 2021`|**`1,177`**|
||`At 31 December 2020`|`1,370`|
|**`8.`**|**`FIXED ASSET INVESTMENTS`**||
|||`Listed`|
|||`investments`|
|||`£`|
||**`MARKET VALUE`**||
||`At 1 January 2021 and`||
||`31 December 2021`|**`6,469`**|
||**`NET BOOK VALUE`**||
||`At 31 December 2021`|**`6,469`**|
||`At 31 December 2020`|`6,469`|
```
There were no investment assets outside the UK.
```
```
continued...
```
```
Page 18
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Notes to the Financial Statements - continued`**
## **`for the Year Ended 31 December 2021`**
|**`9.`**
**`DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
`Trade debtors`
`Prepayments and accrued income`
`Accruals`
**`10.`**
**`CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR`**
`Taxation and social security`
`Other creditors`
**`11.`**
**`MOVEMENT IN FUNDS`**
**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**|`At 1/1/21`
`£`
**`842,979`**
**`156,397`**
**`999,376`**|**`2021`**
`2020`
**`£`**
`£`
**`13,420`**
`-`
**`14,978`**
`44,374`
**`933`**
`-`
**`29,331`**
`44,374`
**`2021`**
`2020`
**`£`**
`£`
**`277`**
`-`
**`23,383`**
`15,711`
**`23,660`**
`15,711`
`Net`
`movement`
`At`
`in funds`
`31/12/21`
`£`
`£`
**`(142,948)`**
**`700,031`**
**`193,014`**
**`349,411`**
**`50,066`**
**`1,049,442`**|`2020`
`£`
`-`
`44,374`
`-`
`44,374`
`2020`
`£`
`-`
`15,711`
`15,711`
`At`
`31/12/21`
`£`
**`700,031`**
**`349,411`**|`2020`
`£`
`-`
`44,374`
`-`|
|---|---|---|---|---|
|||||`44,374`|
|||||`2020`
`£`
`-`
`15,711`|
|||||`15,711`|
```
continued...
```
```
Page 19
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
## **`Notes to the Financial Statements - continued for the Year Ended 31 December 2021`**
## **`11. MOVEMENT IN FUNDS - continued`**
```
Net movement in funds, included in the above are as follows:
```
|**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**
**`Comparatives for movement in funds`**
**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
**`1,021`**
**`193,491`**
**`194,512`**
`At 1/1/20`
`£`
`835,987`
`146,123`
`982,110`|`Resources`
`Movement`
`expended`
`in funds`
`£`
`£`
**`(143,969)`**
**`(142,948)`**
**`(477)`**
**`193,014`**
**`(144,446)`**
**`50,066`**
`Net`
`movement`
`At`
`in funds`
`31/12/20`
`£`
`£`
`6,992`
`842,979`
`10,274`
`156,397`
`17,266`
`999,376`|
|---|---|---|
```
continued...
```
```
Page 20
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
```
## **`11. MOVEMENT IN FUNDS - continued`**
```
Comparative net movement in funds, included in the above are as follows:
```
||`Incoming`|`Resources`|`Movement`|
|---|---|---|---|
||`resources`|`expended`|`in funds`|
||`£`|`£`|`£`|
|**`Unrestricted funds`**||||
|`General fund`|`101,986`|`(94,994)`|`6,992`|
|**`Restricted funds`**||||
|`Restricted Fund`|`126,111`|`(115,837)`|`10,274`|
|**`TOTAL FUNDS`**|`228,097`|`(210,831)`|`17,266`|
|`A current year 12 months and prior year 12 months combined position is as follows:`||||
|||`Net`||
|||`movement`|`At`|
||`At 1/1/20`|`in funds`|`31/12/21`|
||`£`|`£`|`£`|
|**`Unrestricted funds`**||||
|`General fund`|`835,987`|`(135,956)`|`700,031`|
|**`Restricted funds`**||||
|`Restricted Fund`|`146,123`|`203,288`|`349,411`|
|**`TOTAL FUNDS`**|`982,110`|`67,332`|`1,049,442`|
```
continued...
```
```
Page 21
```
```
CANCER TREATMENT AND RESEARCH TRUST
```
```
Notes to the Financial Statements - continued
for the Year Ended 31 December 2021
```
## **`11. MOVEMENT IN FUNDS - continued`**
```
Acurrentyear12monthsandprioryear12monthscombinednetmovementinfunds,included in
the above are as follows:
```
|**`Unrestricted funds`**
`General fund`
**`Restricted funds`**
`Restricted Fund`
**`TOTAL FUNDS`**|`Incoming`
`resources`
`£`
`103,007`
`319,602`
`422,609`|`Resources`
`Movement`
`expended`
`in funds`
`£`
`£`
`(238,963)`
`(135,956)`
`(116,314)`
`203,288`
`(355,277)`
`67,332`|
|---|---|---|
## **`12. RELATED PARTY DISCLOSURES`**
```
There were no related party transactions for the year ended 31 December 2021.
```
```
Page 22
```
## **`CANCER TREATMENT AND RESEARCH TRUST`**
## **`Detailed Statement of Financial Activities`**
## **`for the Year Ended 31 December 2021`**
|**`INCOME AND ENDOWMENTS`**
**`Donations and legacies`**
`Donations`
**`Other trading activities`**
`Recharged expenses`
**`Investment income`**
`Deposit account interest`
`Dividends`
**`Other income`**
`Sundry income`
**`Total incoming resources`**
**`EXPENDITURE`**
**`Raising donations and legacies`**
`Administrator`
`Events expenses`
**`Charitable activities`**
`Pensions`
`Research salaries`
`Research expenses and lab fees`
`Research conferences/meetings`
`Subscriptions`
`Postage and stationery`
`Computer expenses`
`Sundries`
`Depreciation of tangible fixed assets`
`Carried forward`|`2021`
`£`
**`138,354`**
**`41,341`**
**`9`**
**`108`**
**`117`**
**`14,700`**
**`194,512`**
**`14,000`**
**`5,060`**
**`19,060`**
**`214`**
**`59,266`**
**`49,931`**
**`335`**
**`1,191`**
**`423`**
**`240`**
**`-`**
**`389`**
**`111,989`**|`2020`
`£`
`227,995`
`-`
`102`
`-`|
|---|---|---|
|||`102`
`-`|
|||`228,097`
`19,233`
`600`|
|||`19,833`
`-`
`97,012`
`79,895`
`2,428`
`-`
`183`
`217`
`2,687`
`481`
`182,903`|
```
This page does not form part of the statutory financial statements
```
```
Page 23
```
## **`CANCER TREATMENT AND RESEARCH TRUST`**
## **`Detailed Statement of Financial Activities`**
## **`for the Year Ended 31 December 2021`**
|**`Charitable activities`**
`Brought forward`
`Grants to institutions`
**`Support costs`**
**`Management`**
`Insurance`
`Telephone`
`Advertising`
`Sundries`
**`Finance`**
`Bank charges`
**`Governance costs`**
`Accountancy`
`Professional fees`
`Total resources expended`
**`Net income`**|`2021`
`£`
**`111,989`**
**`5,000`**
**`116,989`**
**`47`**
**`34`**
**`38`**
**`209`**
**`328`**
**`782`**
**`6,878`**
**`409`**
**`7,287`**
**`144,446`**
**`50,066`**|`2020`
`£`
`182,903`
`-`|
|---|---|---|
|||`182,903`
`200`
`477`
`-`
`-`|
|||`677`
`70`
`4,805`
`2,543`|
|||`7,348`|
|||`210,831`|
|||`17,266`|
```
This page does not form part of the statutory financial statements
```
```
Page 24
```